177 related articles for article (PubMed ID: 17344303)
21. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
22. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
24. Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events.
Steffens CM; Hope TJ
J Virol; 2004 Sep; 78(17):9573-8. PubMed ID: 15308751
[TBL] [Abstract][Full Text] [Related]
25. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1.
Esser U; Speck RF; Deen KC; Atchison RE; Sweet R; Goldsmith MA
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1845-54. PubMed ID: 11118070
[TBL] [Abstract][Full Text] [Related]
26. Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.
Cammack N
Antivir Chem Chemother; 1999 Mar; 10(2):53-62. PubMed ID: 10335399
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.
Curreli F; Kwon YD; Zhang H; Scacalossi D; Belov DS; Tikhonov AA; Andreev IA; Altieri A; Kurkin AV; Kwong PD; Debnath AK
J Med Chem; 2015 Sep; 58(17):6909-6927. PubMed ID: 26301736
[TBL] [Abstract][Full Text] [Related]
28. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide.
Jiang A; Fisher H; Pomerantz RJ; Dornburg R
Hum Gene Ther; 1999 Nov; 10(16):2627-36. PubMed ID: 10566890
[TBL] [Abstract][Full Text] [Related]
29. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
Schön A; Madani N; Klein JC; Hubicki A; Ng D; Yang X; Smith AB; Sodroski J; Freire E
Biochemistry; 2006 Sep; 45(36):10973-80. PubMed ID: 16953583
[TBL] [Abstract][Full Text] [Related]
30. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
31. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.
Singer II; Scott S; Kawka DW; Chin J; Daugherty BL; DeMartino JA; DiSalvo J; Gould SL; Lineberger JE; Malkowitz L; Miller MD; Mitnaul L; Siciliano SJ; Staruch MJ; Williams HR; Zweerink HJ; Springer MS
J Virol; 2001 Apr; 75(8):3779-90. PubMed ID: 11264367
[TBL] [Abstract][Full Text] [Related]
32. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.
Cormier EG; Tran DN; Yukhayeva L; Olson WC; Dragic T
J Virol; 2001 Jun; 75(12):5541-9. PubMed ID: 11356961
[TBL] [Abstract][Full Text] [Related]
33. Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission.
Qiu M; Wang Q; Chu Y; Yuan Z; Song H; Chen Z; Wu Z
PLoS One; 2012; 7(4):e35906. PubMed ID: 22558266
[TBL] [Abstract][Full Text] [Related]
34. 3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.
Li M; Duan J; Qiu J; Yu F; Che X; Jiang S; Li L
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1455-64. PubMed ID: 23711095
[TBL] [Abstract][Full Text] [Related]
35. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.
Garg H; Francella N; Tony KA; Augustine LA; Barchi JJ; Fantini J; Puri A; Mootoo DR; Blumenthal R
Antiviral Res; 2008 Oct; 80(1):54-61. PubMed ID: 18538869
[TBL] [Abstract][Full Text] [Related]
36. Anionic Carbosilane Dendrimers Destabilize the GP120-CD4 Complex Blocking HIV-1 Entry and Cell to Cell Fusion.
Guerrero-Beltran C; Rodriguez-Izquierdo I; Serramia MJ; Araya-Durán I; Márquez-Miranda V; Gomez R; de la Mata FJ; Leal M; González-Nilo F; Muñoz-Fernández MA
Bioconjug Chem; 2018 May; 29(5):1584-1594. PubMed ID: 29570280
[TBL] [Abstract][Full Text] [Related]
37. Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion.
Rawat SS; Zimmerman C; Johnson BT; Cho E; Lockett SJ; Blumenthal R; Puri A
Mol Membr Biol; 2008 Jan; 25(1):83-94. PubMed ID: 18097956
[TBL] [Abstract][Full Text] [Related]
38. [Replication inhibitors targeting early events in the HIV-1 life cycle].
Ichiyama K; Yamamoto N
Nihon Rinsho; 2002 Apr; 60(4):784-9. PubMed ID: 11968789
[TBL] [Abstract][Full Text] [Related]
39. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
40. Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase.
Paskaleva EE; Lin X; Duus K; McSharry JJ; Veille JC; Thornber C; Liu Y; Lee DY; Canki M
Virol J; 2008 Jan; 5():8. PubMed ID: 18197976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
